Navigation Links
BioDelivery Sciences Announces Completion of Recruitment in BEMA Buprenorphine Phase 3 Chronic Pain Study
Date:4/5/2011

RALEIGH, N.C., April 5, 2011 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced today completion of enrollment in its Phase 3 clinical trial assessing the efficacy and safety of BEMA Buprenorphine for the treatment of moderate to severe chronic pain.

(Logo: https://photos.prnewswire.com/prnh/20110217/CL49801LOGO)

"The completion of enrollment in our Phase 3 efficacy study marks another very important milestone in our clinical development program for BEMA Buprenorphine in the management of chronic pain," stated Dr. Andrew Finn, Executive Vice President of Product Development at BDSI.  "We are very pleased to have achieved our aggressive recruitment and enrollment goals.  This milestone keeps us on target for reporting top-line study results in the third quarter of this year and is consistent with a timeline that would allow for a New Drug Application (NDA) to be filed in the second quarter of 2012."

BDSI believes that there remains a significant unmet medical need for potent new analgesics for the treatment of chronic pain.  The company believes that buprenorphine is an attractive option for development because of its potent analgesic properties, its differentiating characteristics from other opioids and its DEA Schedule III designation, which means there is less addiction potential than Schedule II products.  In addition, BEMA Buprenorphine has the potential to be the first oral transmucosal form of buprenorphine to treat chronic pain in the U.S.  According to Wolters Kluwer, opioid analgesic sales in the U.S. are in excess of $10 billion and growing, and BDSI believes that BEMA Buprenorphine has the potential to exceed $500 million in peak annual sales.

Additional Information on Phase 3 Study Design (BUP-301)

This Phase 3 trial of BEMA Buprenorphine (referred to as BUP-301) is
'/>"/>

SOURCE BioDelivery Sciences International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioDelivery Sciences to Present at the 23rd Annual ROTH OC Growth Stock Conference
2. BioDelivery Sciences Confirms 505(b)(2) Pathway for BEMA Buprenorphine/Naloxone for Opioid Dependence Following FDA Meeting
3. BioDelivery Sciences Announces BEMA Buprenorphine Phase 3 Chronic Pain Study More Than 50% Recruited and on Schedule
4. MonoSol Rx, LLC Files Patent Infringement and False Marking Lawsuit Against BioDelivery Sciences International, Inc., MEDA Pharmaceuticals Inc., and Aveva Drug Delivery Systems, Inc.
5. TCG Lifesciences Expands Pharmaceutical, Biotechnology Research Initiatives with CAS SciFinder®
6. Sofie Biosciences Launches a High Performance, Benchtop Preclinical PET System Using New Generation Detector Technology
7. Caliper Life Sciences Launches Novel COX-2 Probe to Enable Personalized Medicine Research
8. Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
9. Neurocrine Biosciences to Present at the 10th Annual Needham Healthcare Conference
10. Regado Biosciences to Present at the Needham & Companys 10th Annual Healthcare Conference in New York City
11. Newborn Possibilities Fund Awards Grant to Georgia Health Sciences University Foundation to Support Groundbreaking Pediatric Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... , Nov. 20, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: ... Chief Executive Officer, will be presenting at the 26 th ... Palace Hotel in New York . The ... 2:00 PM ET. In addition, Mr. Krakauer and Jorgen ... separate one-on-one meetings during the day. An ...
(Date:11/21/2014)... November 2014 Michael DeMarco (42) ... des 14. Februar 2014 zugetragen hat. Seine Tochter Aly ... Video - http://youtu.be/5cVoMCe0uiE ... mein morgendliches Training zu machen", erzählt Michael DeMarco ... Zeit begeisterte Anhänger der CrossFit-Trainingsmethode. Ich war auf ...
(Date:11/21/2014)...   Wellcentive , the industry leader in ... announced today being named one of the four ... .  Sponsored by Intel, the world leader in ... recognizes companies developing leading-edge technology and unique approaches ... Wellcentive,s Mason Beard , senior ...
Breaking Medicine Technology:Tochter rettet Vater durch Herz-Lungen-Wiederbelebung vor plötzlichem Herztod 2Tochter rettet Vater durch Herz-Lungen-Wiederbelebung vor plötzlichem Herztod 3Wellcentive Named Finalist for 2014 Intel Innovation Award 2Wellcentive Named Finalist for 2014 Intel Innovation Award 3
... BETHESDA, Md., Nov. 1, 2011   For the first ... cause of cystic fibrosis, Kalydeco™ (ivacaftor), is under review ... approval in 2012. This milestone comes as the largest ... Anaheim, Calif., Nov. 3 – 5, 2011. ...
... the world,s leading provider of centralized expert assessments in ... disorders, announced it has been selected as one of ... NJBIZ, New Jersey,s premiere business news publication, annually identifies ... New Jersey,s most dynamic companies who progressively contribute to ...
Cached Medicine Technology:Anaheim to Host World's Largest Gathering on Cystic Fibrosis Research and Care 2MedAvante Is One of NJ's Fastest Growing Companies 2
(Date:11/23/2014)... NY (PRWEB) November 23, 2014 ... allege heart attacks, strokes, deep vein thrombosis and ... in a federal multidistrict litigation (MDL) underway in ... reports. , Court documents updated on November ... Litigation (JPML) show the filing of 259 lawsuits ...
(Date:11/23/2014)... (PRWEB) November 23, 2014 Locks-Magnetic.com, a ... emergency doors. Moreover, all the new products are available ... The marketing manager is proud of the new emergency ... reset automatically. And customers can choose from several colors. ... Buying high quality emergency door release is not as ...
(Date:11/23/2014)... 23, 2014 SWAccessControl.com's high quality access ... Recently, the company has announced its new collection of ... on these high quality power suppliers. All the new ... The special offer lasts until Dec. 20, 2014. , ... them have been supporting it for a long time. ...
(Date:11/23/2014)... Newport Beach, CA (PRWEB) November 23, 2014 ... founder of American Medical Aesthetics & Wellness was ... Dr. Asher Milgrom, Ph.D. is president and CEO of ... Skincare. Dr. Asher Milgrom received a full scholarship ... Sciences and the Medical School at the University of ...
(Date:11/23/2014)... Syngenta lawsuits are now being investigated ... and agribusinesses that have allegedly incurred significant financial damages ... and Agrisure Duracade, genetically modified (GMO) corn seed ... in China. According to a report from Bloomberg News, ... corn imports. Because China is the third-largest American corn ...
Breaking Medicine News(10 mins):Health News:Testosterone Lawsuits Approach 260 in Illinois Federal Court Litigation, Bernstein Liebhard LLP Reports 2Health News:Testosterone Lawsuits Approach 260 in Illinois Federal Court Litigation, Bernstein Liebhard LLP Reports 3Health News:Cheap Access Control Power Supplies Online Now at SWAccessControl.com, Special Offer Until Dec. 20, 2014 2Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 2Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 3Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 4Health News:Syngenta Lawsuits Being Investigated by Wright & Schulte LLC, Following China’s Rejection of Corn Shipments Tainted with Unapproved GMO Seed 2Health News:Syngenta Lawsuits Being Investigated by Wright & Schulte LLC, Following China’s Rejection of Corn Shipments Tainted with Unapproved GMO Seed 3
... of using plant hormones to fight cancer cells. Plant need ... cuttings grow roots. Scientists at the Cancer Research Campaign (CRC), ... kill cancer cells. , Indole ... IAA are added with an enzyme, toxic by products, which ...
... itself by growing new cells after a heart attack. This ... Italy. Dr. Piero Anversa and colleagues of the New York ... called myocytes continued to divide after a heart attack. ... the hearts of 13 people who died within a few ...
... disease, that requires insulin injections daily. Researchers are slowly ... Some medical research centers in the U.S. and Europe ... by transplanting insulin-producing islet cells combined with less toxic ... lives without insulin. , A.M. ...
... size of children's tummies may offer a simple method of ... diabetes at a later age.Among adults, fat around the waist ... studies suggest that it is a better indicator of risk ... ,A large waist is said to be associated ...
... the brain and its function has always left man ... puzzle, some key factors// have been identified that could ... in premature babies and hence help treat prematurity. ... also prevent brain damage repair in neurological diseases like ...
... drinking coffee could decrease the risk of liver cancer.Researchers ... showed self-reported frequency of coffee consumption among more than ... researchers say they found that those who drink coffee ... while those drinking one or more cups a day ...
Cached Medicine News:Health News:Transplant helps diabetes 2Health News:Hyaluronic Acid – A Boon To The Problem Of Premature Infant 2
Nucleus chopper. For bimanual nucleus division....
Phaco chopper, a combination of a Sinskey hook and a pointed "quick chop" tip....
Phaco prechopper with blunt tip double-edge for bi-directional prechopping. For bimanual nucleus prechopping technique....
Titanium. A reverse action instrument with a paddle tips to provide a solid surface to crack the nucleus. When used in scleral tunnel, the reverse action mechanism allows increased flexibility in pos...
Medicine Products: